Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages

• Published in: Cancer Immunology, Immunotherapy Vol. 72; no. 6; pp. 1789 - 1801
• Main Authors: Ehlers, Femke A. I., Mahaweni, Niken M., van de Waterweg Berends, Annet, Saya, Thara, Bos, Gerard M. J., Wieten, Lotte
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2023; Springer Nature B.V
• Subjects: Antibodies; Antibodies, Monoclonal - therapeutic use; Antibody-Dependent Cell Cytotoxicity; Blocking antibodies; Bone growth; Cancer Research; Cell culture; Degranulation; Effector cells; Histocompatibility antigen HLA; Humans; Immunology; Immunostimulation; Immunosuppression; Immunotherapy; Interleukin 2; Interleukin-2 - metabolism; Interleukin-2 - pharmacology; Killer cell immunoglobulin-like receptors; Killer Cells, Natural; Ligands; Macrophages; Macrophages - metabolism; Medicine; Medicine & Public Health; Monoclonal antibodies; Monocytes; Multiple myeloma; Multiple Myeloma - drug therapy; Natural killer cells; Oncology; Original; Original Article; PD-L1 protein; Plasma cells; Tumor cells; Tumor Microenvironment; Tumors; γ-Interferon; NK cells; Tumor-associated cells; Tumor microenvironment; ADCC

Multiple myeloma (MM) is an incurable disease, characterized by malignant plasma cells in the bone marrow. MM growth is largely dependent on the tumor microenvironment (TME), consisting of complex cellular networks that shape a tumor-permissive environment. Within the TME, tumor-associated cells (TA...